APO Research
Talk to an analyst

APO RESEARCH · REPORT

Regorafenib Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Regorafenib Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026186 pages

Choose your research edition.

Industry ResearchRegorafenib Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Regorafenib Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Regorafenib Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Regorafenib Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Regorafenib Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Regorafenib Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Regorafenib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Regorafenib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Regorafenib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Regorafenib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Regorafenib Drugs include Natco, Bayer, Hansoh Pharma, Kelun Pharmaceutical, Qilu Pharmaceutical, Shanghai Acebright Pharmaceuticals, Yangtze River Pharmaceutical, Zhejiang Huayi Pharmaceutical and Chia Tai Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Regorafenib Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Regorafenib Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Regorafenib Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Regorafenib Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Regorafenib Drugs Segment by Company

Natco

Bayer

Hansoh Pharma

Kelun Pharmaceutical

Qilu Pharmaceutical

Shanghai Acebright Pharmaceuticals

Yangtze River Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Regorafenib Drugs Segment by Type

Original Drug

Generic Drug

Regorafenib Drugs Segment by Application

Metastatic Colorectal Cancer

Gastrointestinal Stromal Tumors

Hepatocellular Carcinoma

Regorafenib Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Regorafenib Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Regorafenib Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Regorafenib Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Regorafenib Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Regorafenib Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Regorafenib Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Regorafenib Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Regorafenib Drugs Industry Trends Table 2. Regorafenib Drugs Industry Drivers Table 3. Regorafenib Drugs Industry Opportunities and Challenges Table 4. Regorafenib Drugs Industry Restraints Table 5. Global Regorafenib Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Regorafenib Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Regorafenib Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Regorafenib Drugs Sales Market Share by Manufacturers Table 9. Global Regorafenib Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Regorafenib Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Regorafenib Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Regorafenib Drugs Manufacturers, Product Type & Application Table 13. Global Regorafenib Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Regorafenib Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Original Drug Table 17. Major Manufacturers of Generic Drug Table 18. Global Regorafenib Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Regorafenib Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Regorafenib Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Regorafenib Drugs Sales Market Share by Type (2021-2026) Table 22. Global Regorafenib Drugs Sales Market Share by Type (2027-2032) Table 23. Global Regorafenib Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Regorafenib Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Regorafenib Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Regorafenib Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Regorafenib Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Metastatic Colorectal Cancer Table 29. Major Manufacturers of Gastrointestinal Stromal Tumors Table 30. Major Manufacturers of Hepatocellular Carcinoma Table 31. Global Regorafenib Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Regorafenib Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global Regorafenib Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global Regorafenib Drugs Sales Market Share by Application (2021-2026) Table 35. Global Regorafenib Drugs Sales Market Share by Application (2027-2032) Table 36. Global Regorafenib Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Regorafenib Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global Regorafenib Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global Regorafenib Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Regorafenib Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Regorafenib Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Regorafenib Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Regorafenib Drugs Sales Market Share by Region (2021-2026) Table 44. Global Regorafenib Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Regorafenib Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Regorafenib Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America Regorafenib Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Regorafenib Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe Regorafenib Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Regorafenib Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Regorafenib Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Regorafenib Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Regorafenib Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global Regorafenib Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Regorafenib Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Regorafenib Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Regorafenib Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Regorafenib Drugs Revenue Market Share by Region (2027-2032) Table 63. Natco Company Information Table 64. Natco Business Overview Table 65. Natco Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Natco Regorafenib Drugs Product Portfolio Table 67. Natco Recent Development Table 68. Bayer Company Information Table 69. Bayer Business Overview Table 70. Bayer Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bayer Regorafenib Drugs Product Portfolio Table 72. Bayer Recent Development Table 73. Hansoh Pharma Company Information Table 74. Hansoh Pharma Business Overview Table 75. Hansoh Pharma Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Hansoh Pharma Regorafenib Drugs Product Portfolio Table 77. Hansoh Pharma Recent Development Table 78. Kelun Pharmaceutical Company Information Table 79. Kelun Pharmaceutical Business Overview Table 80. Kelun Pharmaceutical Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Kelun Pharmaceutical Regorafenib Drugs Product Portfolio Table 82. Kelun Pharmaceutical Recent Development Table 83. Qilu Pharmaceutical Company Information Table 84. Qilu Pharmaceutical Business Overview Table 85. Qilu Pharmaceutical Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Qilu Pharmaceutical Regorafenib Drugs Product Portfolio Table 87. Qilu Pharmaceutical Recent Development Table 88. Shanghai Acebright Pharmaceuticals Company Information Table 89. Shanghai Acebright Pharmaceuticals Business Overview Table 90. Shanghai Acebright Pharmaceuticals Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Shanghai Acebright Pharmaceuticals Regorafenib Drugs Product Portfolio Table 92. Shanghai Acebright Pharmaceuticals Recent Development Table 93. Yangtze River Pharmaceutical Company Information Table 94. Yangtze River Pharmaceutical Business Overview Table 95. Yangtze River Pharmaceutical Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Yangtze River Pharmaceutical Regorafenib Drugs Product Portfolio Table 97. Yangtze River Pharmaceutical Recent Development Table 98. Zhejiang Huayi Pharmaceutical Company Information Table 99. Zhejiang Huayi Pharmaceutical Business Overview Table 100. Zhejiang Huayi Pharmaceutical Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Zhejiang Huayi Pharmaceutical Regorafenib Drugs Product Portfolio Table 102. Zhejiang Huayi Pharmaceutical Recent Development Table 103. Chia Tai Tianqing Pharmaceutical Company Information Table 104. Chia Tai Tianqing Pharmaceutical Business Overview Table 105. Chia Tai Tianqing Pharmaceutical Regorafenib Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Chia Tai Tianqing Pharmaceutical Regorafenib Drugs Product Portfolio Table 107. Chia Tai Tianqing Pharmaceutical Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Regorafenib Drugs Distributors List Table 111. Regorafenib Drugs Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Regorafenib Drugs Product Image Figure 2. Global Regorafenib Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Regorafenib Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Regorafenib Drugs Sales (2021-2032) & (K Units) Figure 5. Global Regorafenib Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Regorafenib Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Original Drug Image Figure 9. Generic Drug Image Figure 10. Global Regorafenib Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Regorafenib Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Regorafenib Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Regorafenib Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Regorafenib Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Regorafenib Drugs Revenue Market Share by Type (2021-2032) Figure 16. Metastatic Colorectal Cancer Image Figure 17. Gastrointestinal Stromal Tumors Image Figure 18. Hepatocellular Carcinoma Image Figure 19. Global Regorafenib Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Regorafenib Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Regorafenib Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Regorafenib Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Regorafenib Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Regorafenib Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Regorafenib Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Regorafenib Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Regorafenib Drugs Sales Market Share by Country (2021-2032) Figure 39. China Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Regorafenib Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Regorafenib Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Regorafenib Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Regorafenib Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Regorafenib Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Regorafenib Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Regorafenib Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Regorafenib Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Regorafenib Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Regorafenib Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Metastatic Colorectal Cancer
  • Gastrointestinal Stromal Tumors
  • Hepatocellular Carcinoma
Companies covered
  • Natco
  • Bayer
  • Hansoh Pharma
  • Kelun Pharmaceutical
  • Qilu Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • Yangtze River Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Regorafenib Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Regorafenib Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Regorafenib Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Regorafenib Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Regorafenib Drugs Market Dynamics
  1. 2.1 Regorafenib Drugs Industry Trends
  2. 2.2 Regorafenib Drugs Industry Drivers
  3. 2.3 Regorafenib Drugs Industry Opportunities and Challenges
  4. 2.4 Regorafenib Drugs Industry Restraints
3 Regorafenib Drugs Market by Manufacturers
  1. 3.1 Global Regorafenib Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Regorafenib Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Regorafenib Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Regorafenib Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Regorafenib Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Regorafenib Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Regorafenib Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Regorafenib Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Regorafenib Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Regorafenib Drugs Tier 1, Tier 2, and Tier 3
4 Regorafenib Drugs Market by Type
  1. 4.1 Regorafenib Drugs Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Regorafenib Drugs Sales by Type
  5. 4.2.1 Global Regorafenib Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Regorafenib Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Regorafenib Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Regorafenib Drugs Revenue by Type
  9. 4.3.1 Global Regorafenib Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Regorafenib Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Regorafenib Drugs Revenue Market Share by Type (2021-2032)
5 Regorafenib Drugs Market by Application
  1. 5.1 Regorafenib Drugs Application Introduction
  2. 5.1.1 Metastatic Colorectal Cancer
  3. 5.1.2 Gastrointestinal Stromal Tumors
  4. 5.1.3 Hepatocellular Carcinoma
  5. 5.2 Global Regorafenib Drugs Sales by Application
  6. 5.2.1 Global Regorafenib Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Regorafenib Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Regorafenib Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Regorafenib Drugs Revenue by Application
  10. 5.3.1 Global Regorafenib Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Regorafenib Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Regorafenib Drugs Revenue Market Share by Application (2021-2032)
6 Global Regorafenib Drugs Sales by Region
  1. 6.1 Global Regorafenib Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Regorafenib Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Regorafenib Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Regorafenib Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Regorafenib Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Regorafenib Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Regorafenib Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Regorafenib Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Regorafenib Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Regorafenib Drugs Revenue by Region
  1. 7.1 Global Regorafenib Drugs Revenue by Region
  2. 7.1.1 Global Regorafenib Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Regorafenib Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Regorafenib Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Regorafenib Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Regorafenib Drugs Revenue (2021-2032)
  8. 7.2.2 North America Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Regorafenib Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Regorafenib Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Regorafenib Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Regorafenib Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Natco
  2. 8.1.1 Natco Company Information
  3. 8.1.2 Natco Business Overview
  4. 8.1.3 Natco Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Natco Regorafenib Drugs Product Portfolio
  6. 8.1.5 Natco Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Regorafenib Drugs Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Hansoh Pharma
  14. 8.3.1 Hansoh Pharma Company Information
  15. 8.3.2 Hansoh Pharma Business Overview
  16. 8.3.3 Hansoh Pharma Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hansoh Pharma Regorafenib Drugs Product Portfolio
  18. 8.3.5 Hansoh Pharma Recent Developments
  19. 8.4 Kelun Pharmaceutical
  20. 8.4.1 Kelun Pharmaceutical Company Information
  21. 8.4.2 Kelun Pharmaceutical Business Overview
  22. 8.4.3 Kelun Pharmaceutical Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kelun Pharmaceutical Regorafenib Drugs Product Portfolio
  24. 8.4.5 Kelun Pharmaceutical Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Regorafenib Drugs Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 Shanghai Acebright Pharmaceuticals
  32. 8.6.1 Shanghai Acebright Pharmaceuticals Company Information
  33. 8.6.2 Shanghai Acebright Pharmaceuticals Business Overview
  34. 8.6.3 Shanghai Acebright Pharmaceuticals Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Acebright Pharmaceuticals Regorafenib Drugs Product Portfolio
  36. 8.6.5 Shanghai Acebright Pharmaceuticals Recent Developments
  37. 8.7 Yangtze River Pharmaceutical
  38. 8.7.1 Yangtze River Pharmaceutical Company Information
  39. 8.7.2 Yangtze River Pharmaceutical Business Overview
  40. 8.7.3 Yangtze River Pharmaceutical Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Yangtze River Pharmaceutical Regorafenib Drugs Product Portfolio
  42. 8.7.5 Yangtze River Pharmaceutical Recent Developments
  43. 8.8 Zhejiang Huayi Pharmaceutical
  44. 8.8.1 Zhejiang Huayi Pharmaceutical Company Information
  45. 8.8.2 Zhejiang Huayi Pharmaceutical Business Overview
  46. 8.8.3 Zhejiang Huayi Pharmaceutical Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zhejiang Huayi Pharmaceutical Regorafenib Drugs Product Portfolio
  48. 8.8.5 Zhejiang Huayi Pharmaceutical Recent Developments
  49. 8.9 Chia Tai Tianqing Pharmaceutical
  50. 8.9.1 Chia Tai Tianqing Pharmaceutical Company Information
  51. 8.9.2 Chia Tai Tianqing Pharmaceutical Business Overview
  52. 8.9.3 Chia Tai Tianqing Pharmaceutical Regorafenib Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Chia Tai Tianqing Pharmaceutical Regorafenib Drugs Product Portfolio
  54. 8.9.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Regorafenib Drugs Value Chain Analysis
  2. 9.1.1 Regorafenib Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Regorafenib Drugs Production Mode & Process
  6. 9.2 Regorafenib Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Regorafenib Drugs Distributors
  9. 9.2.3 Regorafenib Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst